Edgewise Therapeutics announces pricing of IPO

Edgewise Therapeutics announces pricing of IPO

BOULDER -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced the pricing of its underwritten initial public offering of 11,000,000 shares of its common stock at a public offering price of $16... Read More

Monday March 29, 2021 0 comments Tags: Boulder, Edgewise Therapeutics

Edgewise Therapeutics appoints Michael Carruthers to be CFO

Edgewise Therapeutics appoints Michael Carruthers to be CFO

BOULDER -- Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael... Read More

Monday October 19, 2020 0 comments Tags: Boulder, Edgewise Therapeutics, Michael Carruthers, Kevin Koch

Edgewise Therapeutics closes $50M Series B financing round

Edgewise Therapeutics closes $50M Series B financing round

BOULDER -- Edgewise Therapeutics, a pre-clinical company developing small molecule therapies for musculoskeletal diseases, announced closing of a $50 million Series B financing round. The... Read More

Monday September 23, 2019 0 comments Tags: Boulder, Edgewise Therapeutics, Kevin Koch